重症监护病房中的血液灌流
本文为叙述性综述,描述血液灌流的技术概念、安全性和临床结果,重点总结吸附治疗在危重症患者中的最新文献与适应证,包括近期随机对照试验和未来研究方向。作者提出,评估脓毒症患者血液灌流疗效的临床试验应采用解释性设计:选择高度同质的患者人群,通过遗传特征和分子生物标志物等富集标准识别亚表型,由多学科培训团队按严格方案实施干预,以最大化疗效与安全性信号。同质队列中混杂未控制变量较少;高度选择人群的试验内部效度好但外推性差。平行设计稳健,通常为监管机构批准新疗法所需;分配隐藏和随机化是减少确认偏倚、观察者偏倚的关键。
要点
- 脓毒症后多器官衰竭源于免疫失调,许多介质为体液因子(细胞因子),理论上可通过血液灌流直接吸附清除。
- 通过器械进行血液灌流可结合内毒素等特定分子或非特异性吸附促炎介质,已尝试研究数十年,结果不一。
- 近期技术进展使生物材料生物相容性更好、可能更高效,吸附治疗应用增多,新适应证和临床工具不断出现。
- 评估脓毒症患者血液灌流疗效的试验应采用解释性设计:高度同质人群、遗传特征和分子生物标志物富集亚表型、多学科培训团队按严格方案实施。
- 样本量小的3期试验可用细胞因子等替代指标作为主要终点,因替代指标阳性结果的可能性高于临床结局;替代指标阳性后再开展探索临床结局的3期试验。
适用人群与场景
- 脓毒症后多器官衰竭的危重症患者。
- 评估血液灌流疗效的临床试验应选择高度同质的患者人群,并通过遗传特征和分子生物标志物等富集标准识别亚表型。
处置流程与药物剂量
- 血液灌流通过器械结合内毒素等特定分子或提供促炎介质的非特异性吸附。
- 干预必须由多学科培训团队实施,并遵循严格方案;偏离方案可能负面影响治疗潜在效应。
- 试验应采用平行设计、分配隐藏和随机化,以最小化确认偏倚和观察者偏倚。
研究设计与关键结果
- 本文为叙述性综述,描述血液灌流的技术概念、安全性和临床结果,重点总结吸附治疗在危重症患者中的最新文献与适应证,包括近期随机对照试验和未来研究方向。
- 作者认为,评估脓毒症患者血液灌流疗效的临床试验应采用解释性设计,包括高度同质人群、遗传特征和分子生物标志物富集亚表型、多学科培训团队按严格方案实施干预,以最大化疗效与安全性信号。
- 同质队列中混杂未控制变量较少;高度选择人群的试验内部效度好但外推性差。
- 平行设计稳健,通常为监管机构批准新疗法所需;分配隐藏和随机化是减少确认偏倚、观察者偏倚的关键。
- 样本量小的3期试验中,细胞因子测定等替代指标适合作为主要终点,因为替代指标阳性结果的可能性高于临床结局;替代指标阳性后,再开展探索临床结局的3期试验,为分配资金提供依据。
证据类型、等级与局限
- 证据类型:叙述性综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒症患者血液灌流疗效的临床试验应采用解释性设计,选择高度同质人群并通过遗传特征和分子生物标志物富集亚表型。
- 作者认为,干预应由多学科培训团队按严格方案实施,并采用平行设计、分配隐藏和随机化以减少偏倚。
- 作者认为,样本量小的3期试验可用细胞因子等替代指标作为主要终点,替代指标阳性后再开展临床结局试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Multiple organ failure following a septic event derives from immune dysregulation. Many of the mediators of this process are humoral factors (cytokines), which could theoretically be cleared by direct adsorption through a process called hemoperfusion. Hemoperfusion through devices, which bind specific molecules like endotoxin or theoretically provide non-specific adsorption of pro-inflammatory mediators has been attempted and studied for several decades with variable results. More recently, technological evolution has led to the increasing application of adsorption due to more biocompatible and possibly more efficient biomaterials. As a result, new indications are developing in this field, and novel tools are available for clinical use. This narrative review will describe current knowledge regarding technical concepts, safety, and clinical results of hemoperfusion. Finally, it will focus on the most recent literature regarding adsorption applied in critically ill patients and their indications, including recent randomized controlled trials and future areas of investigation. Clinical trials for the assessment of efficacy of hemoperfusion in septic patients should apply the explanatory approach. This includes a highly selected homogenous patient population. Enrichment criteria such as applying genetic signature and molecular biomarkers allows the identification of subphenotypes of patients. The intervention must be delivered by a multidisciplinary team of trained personnel. The aim is to maximize the signals for efficacy and safety. In a homogenous cohort, confounding uncontrolled variables are less likely to exist. Trials with highly selected populations have a high internal validity but poor generalizability. The parallel design described in the figure is robust and usually is required by regulatory agencies for the approval of a new treatment. Allocation concealment and randomization are key to minimize bias such as confirmation bias, observer bias. The intervention should be delivered following a strict protocol. Deviations from the protocol might negatively influence the potential effects of the therapies. Surrogates such as cytokine measurement are adequate primary outcomes in phase 3 trials with small sample size because there is a higher likelihood of finding positive results concerning surrogate markers than in respect with clinical outcomes. Once a trial shows positive results concerning surrogate markers, a rationale for another phase 3 trial exploring clinical outcomes is built, justifying the allocation of financial sources to the intended trial.
参考来源
- Ricci Z, Romagnoli S, Reis T, et al. Hemoperfusion in the intensive care unit. Intensive Care Med. 2022. PMID: 35984473. doi:10.1007/s00134-022-06810-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。